Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Preferred Stock Liabilities (2020 - 2021)

Historic Preferred Stock Liabilities for Cytek Biosciences (CTKB) over the last 2 years, with Q2 2021 value amounting to $194.3 million.

  • Cytek Biosciences' Preferred Stock Liabilities changed N/A to $194.3 million in Q2 2021 from the same period last year, while for Jun 2021 it was $194.3 million, marking a year-over-year change of. This contributed to the annual value of $194.3 million for FY2020, which is N/A changed from last year.
  • Per Cytek Biosciences' latest filing, its Preferred Stock Liabilities stood at $194.3 million for Q2 2021.
  • In the past 5 years, Cytek Biosciences' Preferred Stock Liabilities registered a high of $194.3 million during Q4 2020, and its lowest value of $194.3 million during Q4 2020.